Cargando…
Gabapentin enacarbil – clinical efficacy in restless legs syndrome
Restless legs syndrome (RLS) is a sleep-related movement disorder commonly involving an unpleasant urge to move the limbs, typically the legs. Dopaminergic agents represent the first-line therapy for RLS; however, long-term use of such drugs results in worsening symptoms due to “augmentation” or oth...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874339/ https://www.ncbi.nlm.nih.gov/pubmed/20505847 |
_version_ | 1782181460416921600 |
---|---|
author | Agarwal, Pinky Griffith, Alida Costantino, Henry R Vaish, Narendra |
author_facet | Agarwal, Pinky Griffith, Alida Costantino, Henry R Vaish, Narendra |
author_sort | Agarwal, Pinky |
collection | PubMed |
description | Restless legs syndrome (RLS) is a sleep-related movement disorder commonly involving an unpleasant urge to move the limbs, typically the legs. Dopaminergic agents represent the first-line therapy for RLS; however, long-term use of such drugs results in worsening symptoms due to “augmentation” or other adverse events. Gabapentin, an analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), is an anticonvulsant/analgesic agent. Gabapentin is only mildly effective in relieving RLS symptoms, perhaps a result of its poor absorption from the gastrointestinal (GI) tract. Gabapentin enacarbil is a prodrug of gabapentin specifically designed to enhance absorption via the GI tract, and hence provide improved circulating levels of gabapentin on metabolism. Clinical trials to date have demonstrated favorable safety and (compared to traditional gabapentin) improved pharmacokinetics and efficacy in treating RLS symptoms. Thus, gabapentin enacarbil may prove to be a useful drug in treating RLS. An application of gabapentin enacarbil for treatment of RLS is currently pending with FDA for approval. |
format | Text |
id | pubmed-2874339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28743392010-05-26 Gabapentin enacarbil – clinical efficacy in restless legs syndrome Agarwal, Pinky Griffith, Alida Costantino, Henry R Vaish, Narendra Neuropsychiatr Dis Treat Expert Opinion Restless legs syndrome (RLS) is a sleep-related movement disorder commonly involving an unpleasant urge to move the limbs, typically the legs. Dopaminergic agents represent the first-line therapy for RLS; however, long-term use of such drugs results in worsening symptoms due to “augmentation” or other adverse events. Gabapentin, an analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), is an anticonvulsant/analgesic agent. Gabapentin is only mildly effective in relieving RLS symptoms, perhaps a result of its poor absorption from the gastrointestinal (GI) tract. Gabapentin enacarbil is a prodrug of gabapentin specifically designed to enhance absorption via the GI tract, and hence provide improved circulating levels of gabapentin on metabolism. Clinical trials to date have demonstrated favorable safety and (compared to traditional gabapentin) improved pharmacokinetics and efficacy in treating RLS symptoms. Thus, gabapentin enacarbil may prove to be a useful drug in treating RLS. An application of gabapentin enacarbil for treatment of RLS is currently pending with FDA for approval. Dove Medical Press 2010-05-06 2010 /pmc/articles/PMC2874339/ /pubmed/20505847 Text en © 2010 Agarwal et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Expert Opinion Agarwal, Pinky Griffith, Alida Costantino, Henry R Vaish, Narendra Gabapentin enacarbil – clinical efficacy in restless legs syndrome |
title | Gabapentin enacarbil – clinical efficacy in restless legs syndrome |
title_full | Gabapentin enacarbil – clinical efficacy in restless legs syndrome |
title_fullStr | Gabapentin enacarbil – clinical efficacy in restless legs syndrome |
title_full_unstemmed | Gabapentin enacarbil – clinical efficacy in restless legs syndrome |
title_short | Gabapentin enacarbil – clinical efficacy in restless legs syndrome |
title_sort | gabapentin enacarbil – clinical efficacy in restless legs syndrome |
topic | Expert Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874339/ https://www.ncbi.nlm.nih.gov/pubmed/20505847 |
work_keys_str_mv | AT agarwalpinky gabapentinenacarbilclinicalefficacyinrestlesslegssyndrome AT griffithalida gabapentinenacarbilclinicalefficacyinrestlesslegssyndrome AT costantinohenryr gabapentinenacarbilclinicalefficacyinrestlesslegssyndrome AT vaishnarendra gabapentinenacarbilclinicalefficacyinrestlesslegssyndrome |